|OncoCyte to Report Fourth Quarter and Full-Year 2018 Financial Results on Monday, April 1, 2019|
March 25, 2019
|ALAMEDA, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31, 2018, on Monday, April 1, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Monday, April 1, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along wi... |
|BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019|
March 18, 2019
|ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2019--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that Brian M.
Culley, Chief Executive Officer, will be presenting at the Oppenheimer &
Co. 29th Annual Healthcare Conference on March 20th,
2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the
Track 2 Room in New York, NY.
|BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update|
March 14, 2019
|Completed Acquisition of Asterias Biotherapeutics, Inc.
Completed Distribution of AgeX Therapeutics Shares to BioTime
Entered Into Exclusive Collaboration with Orbit Biomedical Ltd.
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 14, 2019--
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, reported
financial and operating resul... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|